サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1771491

微小残留病変検査の世界市場：市場規模・シェア・動向分析 (技術別・がんの種類別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology, By Cancer Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 320 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
微小残留病変検査の世界市場：市場規模・シェア・動向分析 (技術別・がんの種類別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年06月06日
発行: Grand View Research
ページ情報: 英文 320 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

微小残留病変検査市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の微小残留病変検査の市場規模は、2025年から2030年にかけて10.1%のCAGRを記録し、2030年までに45億米ドルに達すると推定されています。

新規の診断・予後アッセイとしてのMRD検査の採用は、あらゆる種類の血液悪性腫瘍を治療するための治療レジメンの確実な調整を促進します。治療成績の測定は、所定のがん治療レジームを成功裏に採用するために極めて重要です。

MRDは、がんの病態をよりよく理解し、最終的に治療成果を活用するために重要な分子情報を生み出します。そのため、MRD検査は、腫瘍学に基づく研究のための数多くの臨床試験におけるエンドポイント分析段階としてますます使用されるようになっており、また、個人の遺伝的特性による治療成績のばらつきを効果的に記録しています。例えば、2020年11月、Adaptive Biotechnologies CorporationはGlaxoSmithKline plc.と提携し、GSKの血液治療薬による治療後の残存がん細胞の評価にclonoSEQアッセイを使用することになりました。

他の関連療法による腫瘍の外科的切除は、本質的にがん細胞が完全に除去されることを意味しません。がんの痕跡は体の一部や血流に残る可能性があります。このような残存細胞の診断は、さらなる化学療法や放射線療法の必要性を判断する上で極めて重要です。研究者たちは、MRDを効果的に検出する非侵襲的な検査を考案しています。例えば、2022年2月、C2i Genomics社の血液検査は、外科的腫瘍学的処置後の残存がん細胞を定量化しました。このC2inform検査はCEマークの認可も得ており、欧州では「software-as-a-medical-device」MRD検査として提供されています。

がん治療薬は、関連する臨床エビデンスを用いて、腫瘍細胞の残留を避けるように効果的に調整され、また、個人の特定の進行プロファイルに基づいて個別化されます。数多くの調査研究が、効果的な治療のために個人の遺伝的特性を考慮する必要性を後押ししています。例えば、2022年10月、Adaptive Biotechnologies Corporationは、血液がんにおけるMRDモニタリングへのアクセスを増やすためにEpicと提携しました。さらに、2021年2月、Natera Inc.はPersonalis Inc.と提携し、治療モニタリング体制とMRDの評価を効果的に設計するために、NeXT腫瘍プロファイリング（Personalis社製）と個別化ctDNAプラットフォームSignatera診断製品（Natera, Inc.製）を統合することで、個別化がん治療の成果を理解しようとしています。

微小残留病変検査市場レポートハイライト

  • 技術別では、MRD検査の高感度と幅広い適用性により、フローサイトメトリー部門が2024年の微小残留病変検査市場で圧倒的なシェアを占めました。
  • がん種別では、血液悪性腫瘍の有病率の増加により、血液悪性腫瘍が2024年に68.58%の収益シェアで市場を独占しました。
  • 最終用途別では、病院・専門クリニックが2024年に最も高い収益を上げるセグメントです。
  • 2024年の微小残留病変検査市場は北米が支配的でしたが、これは同地域における血液悪性腫瘍の有病率が上昇しているためであり、その背景には償還制度の整備があります。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 微小残留病変検査市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 微小残留病変検査市場：分析ツール
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 微小残留病変検査市場：技術別の推定・動向分析

  • 市場シェア：技術別（2024年・2030年）
  • セグメントダッシュボード
  • 世界の微小残留病変検査市場：技術別の展望
  • 市場規模の予測と動向分析（2018年・2030年）
    • フローサイトメトリー
    • ポリメラーゼ連鎖反応（PCR）
    • 次世代シーケンシング（NGS）
    • その他

第5章 微小残留病変検査市場：がんの種類別の推定・動向分析

  • 市場シェア：がんの種類別（2024年・2030年）
  • セグメントダッシュボード
  • 世界の微小残留病変検査市場：がんの種類別の展望
  • 市場規模の予測と動向分析（2018年・2030年）
    • 造血悪性腫瘍
    • 固形腫瘍

第6章 微小残留病変検査市場：最終用途別の推定・動向分析

  • 市場シェア：最終用途別（2024年・2030年）
  • セグメントダッシュボード
  • 世界の微小残留病変検査市場：最終用途別の展望
  • 市場規模の予測と動向分析（2018年・2030年）
    • 病院・専門クリニック
    • 学術研究機関
    • 診断検査室
    • その他

第7章 微小残留病変検査市場：地域別の推定・動向分析

  • 市場シェア：技術別（2024年・2030年）
  • 市場ダッシュボード：地域別
  • 世界市場のスナップショット：地域別
  • 市場規模の予測と動向分析（2018年・2030年）
  • 北米
    • 北米：SWOT分析
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州：SWOT分析
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • アジア太平洋：SWOT分析
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ラテンアメリカ：SWOT分析
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカ：SWOT分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 最新動向と影響分析：主要参入企業別
  • 企業/競合の分類
  • ベンダー情勢
    • 主要な流通業者・チャネルパートナーの一覧
    • 主要顧客
    • 主要企業の市場シェア分析 (2024年)
    • Exact Sciences Corporation.
    • GRAIL, LLC
    • Veracyte, Inc.
    • Natera, Inc.
    • Guardant Health
    • F. Hoffmann-La Roche Ltd
    • FOUNDATION MEDICINE, INC.
    • QIAGEN
    • mdxhealth
    • Bio-Techne.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global Minimal Residual Disease Testing Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 6 Global Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 7 Global Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8 North America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 10 North America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 11 North America Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12 U.S Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 13 U.S Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 14 U.S Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15 Canada Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 16 Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 19 Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 21 Europe Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 22 Europe Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 23 Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 25 UK Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 26 UK Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 27 UK Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Germany Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 29 Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 30 Germany Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 31 France Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 32 France Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 33 France Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34 Italy Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 35 Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 36 Italy Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 Spain Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 38 Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 39 Spain Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 41 Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 44 Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 45 Sweden Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 46 Norway Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 47 Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 48 Norway Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 54 Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 55 Japan Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56 China Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 57 China Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 58 China Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 India Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 60 India Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 61 India Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 63 South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 64 South Korea Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65 Australia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 66 Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 67 Australia Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 69 Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 70 Thailand Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 71 Latin America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 73 Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 74 Latin America Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 76 Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 77 Brazil Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 79 Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 80 Argentina Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 81 Middle East and Africa Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East and Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 86 South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 92 UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 93 UAE Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Minimal Residual Disease Testing: market outlook
  • Fig. 14 Minimal Residual Disease Testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook.
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Minimal Residual Disease Testing driver impact
  • Fig. 20 Minimal Residual Disease Testing restraint impact
  • Fig. 21 Minimal Residual Disease Testing strategic initiatives analysis
  • Fig. 22 Minimal Residual Disease Testing: Technology movement analysis
  • Fig. 23 Minimal Residual Disease Testing: Technology outlook and key takeaways
  • Fig. 24 Flow Cytometry market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 25 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 26 Next Generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 28 Minimal Residual Disease Testing: Cancer movement analysis
  • Fig. 29 Minimal Residual Disease Testing: Cancer outlook and key takeaways
  • Fig. 30 Hematological Malignancy market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 31 Leukemia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 32 Lymphoma market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 33 Solid Tumors market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 34 Minimal Residual Disease Testing: End use movement analysis
  • Fig. 35 Minimal Residual Disease Testing: End use outlook and key takeaways
  • Fig. 36 Hospitals & Specialty Clinics market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 37 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 38 Academic and Research Institutions market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 39 Others market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 40 Global minimal residual disease testing market: Regional movement analysis
  • Fig. 41 Global minimal residual disease testing market: Regional outlook and key takeaways
  • Fig. 42 Global minimal residual disease testing market shares and leading players
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 45 U.S.
  • Fig. 46 U.S. market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 47 Canada
  • Fig. 48 Canada market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 49 Mexico
  • Fig. 50 Mexico market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 57 France
  • Fig. 58 France market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 66 Sweden
  • Fig. 67 Sweden market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 68 Norway
  • Fig. 69 Norway market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 70 Asia Pacific
  • Fig. 71 Asia Pacific market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 72 China
  • Fig. 73 China market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 74 Japan
  • Fig. 75 Japan market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 76 India
  • Fig. 77 India market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 79 Thailand
  • Fig. 80 Thailand market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 81 South Korea
  • Fig. 82 South Korea market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 85 Latin America
  • Fig. 86 Latin America market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 87 Brazil
  • Fig. 88 Brazil market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecast, 2018 - 2030 USD Million
  • Fig. 101 Market share of key market players- Minimal Residual Disease Testing
目次
Product Code: GVR-4-68040-016-3

Minimal Residue Disease Testing Market Growth & Trends:

The global minimal residual disease testing market size is estimated to reach USD 4.50 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime.

MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK's hematology therapeutics.

Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a 'software-as-a-medical-device' MRD test in Europe.

Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera's diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

Minimal Residue Disease Testing Market Report Highlights:

  • By technology, the flow cytometry segment held a dominant share in the minimal residual disease testing market in 2024, owing to the high sensitivity and wide applicability of MRD testing.
  • By cancer type, the hematological malignancy cancer dominated the market with a revenue share of 68.58% in 2024, owing to the increasing prevalence of hematological malignancy.
  • By end-use, the hospitals and specialty clinics segment is the highest revenue-generating segment in 2024, owing to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics.
  • North America dominated the minimal residual disease testing market in 2024, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Cancer Type
    • 1.2.3. End use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology Outlook
    • 2.2.2. Test Type Outlook
    • 2.2.3. Cancer Type Outlook
    • 2.2.4. End use Outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Minimal Residual Disease Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Minimal Residual Disease Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Minimal Residual Disease Testing Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Minimal Residual Disease Testing Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Flow Cytometry
      • 4.4.1.1. Flow Cytometry market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Polymerase Chain Reaction (PCR)
      • 4.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Next Generation Sequencing (NGS)
      • 4.4.3.1. Next Generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Minimal Residual Disease Testing Market: Cancer Type Estimates & Trend Analysis

  • 5.1. Cancer Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Minimal Residual Disease Testing Market by Cancer Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hematological Malignancy
      • 5.4.1.1. Hematological Malignancy market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Leukemia
        • 5.4.1.2.1. Leukemia market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Lymphoma
        • 5.4.1.3.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Solid Tumors
      • 5.4.2.1. Solid Tumors market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Minimal Residual Disease Testing Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Minimal Residual Disease Testing Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals and Specialty Clinics
      • 6.4.1.1. Hospitals and Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Academic and Research Institutes
      • 6.4.2.1. Academic and Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Diagnostic Laboratories
      • 6.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Minimal Residual Disease Testing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
  • 7.5. North America
    • 7.5.1. North America: SWOT Analysis
    • 7.5.2. U.S.
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe: SWOT Analysis
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Regulatory framework
      • 7.6.9.3. Competitive scenario
      • 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific: SWOT Analysis
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Regulatory framework
      • 7.7.7.3. Competitive scenario
      • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America: SWOT Analysis
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA: SWOT Analysis
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Regulatory framework
      • 7.9.5.3. Competitive scenario
      • 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Exact Sciences Corporation.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GRAIL, LLC
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Veracyte, Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Natera, Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Guardant Health
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. F. Hoffmann-La Roche Ltd
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. FOUNDATION MEDICINE, INC.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. QIAGEN
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. mdxhealth
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Bio-Techne.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives